metoprine has been researched along with Carcinoma 256, Walker in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duch, DS; Grivsky, EM; Lee, S; Nichol, CA; Sigel, CW | 1 |
| Bertino, JR; Horváth, C; Kalghatgi, KK; Moroson, BA | 1 |
2 other study(ies) available for metoprine and Carcinoma 256, Walker
| Article | Year |
|---|---|
Synthesis and antitumor activity of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine.
Topics: Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Folic Acid Antagonists; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Methotrexate; Pyrimidines; Rats | 1980 |
Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
Topics: Animals; Carboxypeptidases; Carcinoma 256, Walker; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Folic Acid Antagonists; Male; Pyrimethamine; Rats; Time Factors; Triazines | 1979 |